Sopharma AD Past Earnings Performance

Past criteria checks 5/6

Sopharma AD has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 9.2% per year. Sopharma AD's return on equity is 13.2%, and it has net margins of 5%.

Key information

16.9%

Earnings growth rate

17.3%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate9.2%
Return on equity13.2%
Net Margin5.0%
Next Earnings Update29 Mar 2024

Recent past performance updates

Recent updates

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

Feb 20
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Feb 05
How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Jan 22
Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06
Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Dec 22
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Dec 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Nov 19
Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Jul 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Revenue & Expenses Breakdown
Beta

How Sopharma AD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BUL:SFA Revenue, expenses and earnings (BGN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,888952550
30 Sep 231,832812390
30 Jun 231,787912300
31 Mar 231,742832240
31 Dec 221,672712160
30 Sep 221,6511072230
30 Jun 221,6551012230
31 Mar 221,629922220
31 Dec 211,611892250
30 Sep 211,608582250
30 Jun 211,527412190
31 Mar 211,460372140
31 Dec 201,446302130
30 Sep 201,375751940
30 Jun 201,353852010
31 Mar 201,340822000
31 Dec 191,288871960
30 Sep 191,257352000
30 Jun 191,231301910
31 Mar 191,209311920
31 Dec 181,188281870
30 Sep 181,166341830
30 Jun 181,125321780
31 Mar 181,077351660
31 Dec 171,024401580
30 Sep 17965521490
30 Jun 17930531420
31 Mar 17906571420
31 Dec 16883511390
30 Sep 16874291400
30 Jun 16867211410
31 Mar 16878231380
31 Dec 15883211410
30 Sep 15883241450
30 Jun 15877291430
31 Mar 15860171410
31 Dec 14852201420
30 Sep 14833191350
30 Jun 14811191360
31 Mar 14793241340
31 Dec 13767291280
30 Sep 13738301270
30 Jun 13717391210
31 Mar 13707421200

Quality Earnings: SFA has high quality earnings.

Growing Profit Margin: SFA's current net profit margins (5%) are higher than last year (4.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SFA's earnings have grown by 16.9% per year over the past 5 years.

Accelerating Growth: SFA's earnings growth over the past year (33.9%) exceeds its 5-year average (16.9% per year).

Earnings vs Industry: SFA earnings growth over the past year (33.9%) exceeded the Pharmaceuticals industry 4.7%.


Return on Equity

High ROE: SFA's Return on Equity (13.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.